Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Pharmacokinetic considerations in the treatment of multiple sclerosis with interferon-β.
Human endogenous retrovirus-K contributes to motor neuron disease.
Association of Deep Gray Matter Damage With Cortical and Spinal Cord Degeneration in Primary Progressive Multiple Sclerosis.
Multiple sclerosis and fatigue: A review on the contribution of inflammation and immune-mediated neurodegeneration.
Quantitation of Teriflunomide in Human Serum/Plasma Across a 40,000-Fold Concentration Range by LC/MS/MS.
Programmed Death Ligand-1 on Microglia Regulates Th1 Differentiation via Nitric Oxide in Experimental Autoimmune Encephalomyelitis.
Blocking mitochondrial calcium release in Schwann cells prevents demyelinating neuropathies.
Use of herbal remedies by multiple sclerosis patients: a nation-wide survey in Italy.
Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis.
Transorbital sonography in CIDP patients: No evidence for optic nerve hypertrophy.
Clinical response and tolerability of fampridine in clinical practice.
The Relationships Between Apathy and Executive Dysfunction in Multiple Sclerosis.
Type I IFN receptor controls activated TYK2 in the nucleus: Implications for EAE therapy.
Longitudinal 7-year follow-up of chronic pain in persons with multiple sclerosis in the community.
[Alemtuzumab is a new drug based on monoclonal antibodies for treatment multiple sclerosis: treatment possibilities and risks(review)].
Role of regulatory T cells in pathogenesis and biological therapy of multiple sclerosis.
Pediatric demyelinating diseases.
Correction: Imatinib Ameliorates Neuroinflammation in a Rat Model of Multiple Sclerosis by Enhancing Blood-Brain Barrier Integrity and by Modulating the Peripheral Immune Response.
Delayed Recovery of Leg Fatigue Symptoms Following a Maximal Exercise Session in People With Multiple Sclerosis.
Risk factors related to cardiovascular diseases and the metabolic syndrome in multiple sclerosis - a systematic review.
Teriflunomide.
Lipid Resonance on In Vivo Proton MR Spectroscopy: Value of Other Metabolites in Differential Diagnosis.
The Stress-Buffering Effects of Hope on Adjustment to Multiple Sclerosis.
Reduced serum vitamin D levels in neuromyelitis optica.
Impact of transcranial direct current stimulation on fatigue in multiple sclerosis.
Pages
« first
‹ previous
…
546
547
548
549
550
551
552
553
554
…
next ›
last »